184040-47-9

Upstream product

• 98-03-3 thiophene-2-carbaldehyde 
• 100-51-6 benzyl alcohol 
• 636-72-6 2-thiophenemethanol 
• 100-39-0 benzyl bromide 
• 13679-77-1 (thiophen-2-yl)methyl acetate 

Downstream Products

• 1191070-53-7 (S)-(5-benzyloxymethyl-thiophen-2-yl)hydroxyacetic acid butyl ester 
• 1403938-46-4 8-(5-((benzyloxy)methyl)thiophen-2-yl)-1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione 
• 1609244-49-6 5,5'-bis(benzyloxymethyl)-2,2'-bithiophene 

Relevant academic research and scientific papers

Reductive Etherification via Anion-Binding Catalysis

Reductive condensations of alcohols with aldehydes/ketones to generate ethers are catalyzed by a readily accessible thiourea organocatalyst that operates in combination with HCl. 1,1,3,3-tetramethyldisiloxane serves as a convenient reducing reagent. This strategy is applicable to challenging substrate combinations and exhibits functional group tolerance. Competing reductive homocoupling of the carbonyl component is suppressed.

Palladium-catalyzed C-H homocoupling of furans and thiophenes using oxygen as the oxidant

A general and efficient palladium-catalyzed intermolecular direct C-H homocoupling of furans and thiophenes has been developed. The reaction is characterized by using molecular oxygen as the sole oxidant and complete C5-position regioselectivity. Both C2- and C3-substituted furans or thiophenes are appropriate substrates. The approach provides a straightforward, facile, and economical route to bifurans and bithiophenes under mild reaction conditions.

An efficient labeling strategy of drug like molecules with functionalized alkyl linkers using CH-activation

Heterocyclic drugs can be cross-coupled with functionalized thiophene derivatives under dehydrogenative conditions using Pd-catalysts. Upon reductive desulfurization an alkyl linker is introduced with a functional group at its terminus, which will allow the immobilization of the drug molecule onto a solid support for chemical proteomics.

Sulfonamides for treatment of endothelin-mediated disorders

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides a

Sulfonamides for treatment of endothelin-mediated disorders

Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Formulation of sulfonamides for treatment of endothelin-mediated disorders

Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of so

Synthesis of alkyl heteryl ethers from acetates under interphase catalysis conditions in a liquid/solid system

The reaction of acetates of heterocyclic alcohols with alkyl halides in the two-phase catalytic system of solid KOH/C6H6/18-crown-6 at room temperature leads selectively to the formation of the corresponding heterocyclic ethers in 32-93% yield. 1998 Plenum Publishing Corporation.